Condition: Ewing Sarcoma · Rhabdomyosarcoma · Synovial Sarcoma · Sponsor: University Hospital Tuebingen
The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine. Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.
This description comes directly from the study's public registry record.
Martin Ebinger, Prof. Dr. · +49 7071 2983781 · martin.ebinger@med.uni-tuebingen.de
Joachim Rupprecht, Dr. · joachim.rupprecht@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| Pediatrics III, West German Cancer Centre, University Hospital | Essen, Germany | Not Yet Recruiting |
| Universitätsklinikum, Klinik für Kinder- und Jugendmedizin | Frankfurt am Main, Germany | Not Yet Recruiting |
| Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum | Freiburg im Breisgau, Germany | Not Yet Recruiting |
| University Children's Hostpital | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06094101